Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission
Buprenorphine-naloxone was associated with significantly reduced mortality and increased remission rates for patients with opioid use disorder and should be used as a primary treatment. The recognition and implementation of treatment options like buprenorphine-naloxone is vital in alleviating the impact of OUD.
Authors
- George Golovko (ORCID: https://orcid.org/0000-0003-4609-2767)
- Kathryn A. Cunningham
- Yeoshina Pillay
- Krishna K Paul (ORCID: https://orcid.org/0000-0002-9829-1250)
- Lauren G Bothwell (ORCID: https://orcid.org/0009-0003-2665-9129)
- Timothy Hill (ORCID: https://orcid.org/0009-0009-8942-5091)
- Stanley Troung
- Christian G Frey
- Laura Vita Q Paglicawan
- Dietrich Jehle (ORCID: https://orcid.org/0000-0003-3056-7481)
Institutions
- The University of Texas Medical Branch at Galveston (US)
- Michigan State University (US)
Publication Details
- Journal
- Western Journal of Emergency Medicine
- Published
- 2024-09-06
- DOI
- https://doi.org/10.5811/westjem.18569
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences